Get the Stockscreener App
11.12
0.18%
0.025
Mink Therapeutics Inc stock is traded at $11.12, with a volume of 23,481.
It is up +0.18% in the last 24 hours and up +20.87% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
See More
Previous Close:
$11.10
Open:
$11.44
24h Volume:
23,481
Relative Volume:
0.81
Market Cap:
$43.99M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-15.24
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
+21.40%
1M Performance:
+20.87%
6M Performance:
+32.54%
1Y Performance:
+32.00%
1-Day Range:
$10.80
$11.99
1-Week Range:
$7.32
$13.79
52-Week Range:
$4.5601
$19.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.10 | 43.99M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.97 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.04 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.65 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.27 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.22 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mink Therapeutics Inc Stock (INKT) Latest News
Stocks Surge Across Health Services and Industry Sectors: Nuvve, Exagen, and Flexsteel Lead the Way - HPBL
Stock market news: Nuvve Holding +47.92%, Flexsteel Industries +28.15% among top gainers during mid day trading - Business Upturn
MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Significant Growth in Short Interest - MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Mink Therapeutics stock hits 52-week high at $8.84 - MSN
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Mink Therapeutics stock hits 52-week high at $8.84 By Investing.com - Investing.com Canada
MiNK Therapeutics announces reverse stock split - MSN
MiNK Therapeutics (NASDAQ:INKT) Shares to Reverse Split on Tuesday, January 28th - Defense World
MiNK Therapeutics, Inc. Announces a Presentation at the American Society of Clinical Oncology Gastrointestinal Cancers - Marketscreener.com
MiNK Therapeutics presents cancer study at ASCO GI - Investing.com India
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - The Manila Times
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics presents cancer study at ASCO GI By Investing.com - Investing.com South Africa
MiNK Therapeutics announces reverse stock split By Investing.com - Investing.com UK
Kinaxis Inc. (TSE:KXS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
MiNK Therapeutics (NASDAQ:INKT) vs. Evaxion Biotech A/S (NASDAQ:EVAX) Head to Head Analysis - Defense World
Nerdy, Inc. (NYSE:NRDY) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Stock Market Movers Today • Top Gainers & Losers - Benzinga
MML Investors Services LLC Acquires Shares of 12,147 Sabre Co. (NASDAQ:SABR) - Defense World
Carbon Streaming (OTCMKTS:OFSTF) Stock Price Up 5.5% – What’s Next? - Defense World
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewswire
Claire's Place Foundation Wraps up 2024 with Record-Breaking Events & Exciting Announcements for 2025 - The Manila Times
Mink Therapeutics stock hits 52-week low at $0.56 amid market challenges - Investing.com Australia
Mink Ventures Commences Diamond Drill Program at Warren Nickel Copper Cobalt Project, Timmins, Ontario - Yahoo Finance
ATEX Resources (OTCMKTS:ECRTF) Stock Price Down 0.7% – Here’s Why - Defense World
Domo’s (DOMO) Market Outperform Rating Reiterated at JMP Securities - Defense World
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Business Wire
FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering - BioSpace
Arovella heads toward clinic with CAR-19-iNKT cells - BioWorld Online
Comparing MiNK Therapeutics (NASDAQ:INKT) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
Geenex Developed Mink Solar Project Approved by Ohio Power Siting Board - Yahoo Finance
Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World
Comparing Fractyl Health (GUTS) and Its Peers - Defense World
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Midwest Energy Emissions Becomes Birchtech Corp. and Announces Equity Incentive Plan AmendmentsOn October 29, 2024, Birchtech Corp. (formerly Midwest Energy Emissions Corp.) filed a Form 8-K with the SEC, detailing recent corporate changes and u - Defense World
Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):